A truly deadly quartet: Obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia

Vijay Nambi, MD
Department of Internal Medicine, The Cleveland Clinic

Byron J. Hoogwerf, MD
Director, Internal Medicine Residence Program, Department of Endocrinology, The Cleveland Clinic

Dennis L. Sprecher, MD
Head, Section of Preventive Cardiology and Cardiac Rehabilitation, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Dennis L. Sprecher, MD, Department of Cardiology, C51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail sprechd@ccf.org

Dr. Sprecher has indicated that he has received grant or research support from the Astra/Zeneca/Merck corporation and is also on its speakers’ bureau. He also serves as a consultant for International Medical Innovations, Inc.

This paper discusses treatments that are not approved by the US Food and Drug Administration for some of the uses under discussion.

Vijay Nambi, MD
Department of Internal Medicine, The Cleveland Clinic

Byron J. Hoogwerf, MD
Director, Internal Medicine Residence Program, Department of Endocrinology, The Cleveland Clinic

Dennis L. Sprecher, MD
Head, Section of Preventive Cardiology and Cardiac Rehabilitation, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Dennis L. Sprecher, MD, Department of Cardiology, C51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail sprechd@ccf.org

Dr. Sprecher has indicated that he has received grant or research support from the Astra/Zeneca/Merck corporation and is also on its speakers’ bureau. He also serves as a consultant for International Medical Innovations, Inc.

This paper discusses treatments that are not approved by the US Food and Drug Administration for some of the uses under discussion.

Vijay Nambi, MD
Department of Internal Medicine, The Cleveland Clinic

Byron J. Hoogwerf, MD
Director, Internal Medicine Residence Program, Department of Endocrinology, The Cleveland Clinic

Dennis L. Sprecher, MD
Head, Section of Preventive Cardiology and Cardiac Rehabilitation, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Dennis L. Sprecher, MD, Department of Cardiology, C51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail sprechd@ccf.org

Dr. Sprecher has indicated that he has received grant or research support from the Astra/Zeneca/Merck corporation and is also on its speakers’ bureau. He also serves as a consultant for International Medical Innovations, Inc.

This paper discusses treatments that are not approved by the US Food and Drug Administration for some of the uses under discussion.